Lexeo Therapeutics, Inc. · NASDAQ:LXEO
Lexeo Therapeutics — Corporate Update (June 2026)
16 slides from Lexeo Therapeutics's corporate update, Jun 15, 2026
Slide 1: Lexeo Therapeutics LX2006 Regulatory Update
Lexeo Therapeutics LX2006 Regulatory Update June 15, 2026 Exhibit 99.2
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, statements regarding Lexeo’s expectations and plans regarding its current product candidates and programs, including statements regardi
Slide 3: Reshaping heart health with genetic medicine for rare cardiac disease
Dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular disease is treated Genetic medicine leader with rare cardiac disease focus Proven experience in the clinic Platform designed for safety and scalability Individuals and families impacted by F
Slide 4: Finalized pivotal study protocol for LX2006, potential BLA submission in 1H 2028
Finalized pivotal study protocol for LX2006, with potential BLA submission in 1H 2028 BLA = biologics license application, LVMI = left ventricular mass index, mFARS = modified Friedreich Ataxia Rating Scale, KCCQ = Kansas City Cardiomyopathy Questionnaire, Hs = high sensitivity. Pivotal Protocol for
Slide 5: Today's update and the path forward for LX2006
Today’s update and the path forward for LX2006 2022 2023 2024 2025 2026 2027 SUNRISE-FA IND cleared SUNRISE-FA enrollment complete (Q4 24) CLARITY-FA initiated (Q2 25) SUNRISE-FA2 initiation (Q2 26) Potential topline data (2H 27) Today We Are Providing a Regulatory Update Regarding the SUNRISE-FA 2
Slide 6: LX2006 for the Treatment of Friedreich Ataxia
LX2006 for the Treatment of Friedreich Ataxia
Slide 7: Cardiac complications are the leading cause of death in Friedreich Ataxia
Cardiac complications are the leading cause of death in Friedreich Ataxia 1 - Payne R.M. JACC Basic Transl Sci, 2022;13;7(12):1267-1283. - Friedreich’s Ataxia Research Alliance, 2024. - Norrish G., et al. Arch Dis Child, 2022;107(5), 450–455. - Reetz, K., et al. Lancet Neurol, 2025;24(7):614-624. FA
Slide 8: LX2006 has the potential to treat the root cause of FA cardiomyopathy
LX2006 has the potential to treat the root cause of FA cardiomyopathy: significant decrease in frataxin in the heart Frataxin deficiency results in mitochondrial dysfunction and leads to deficient energy production in hypertrophic cardiomyocytes Transfer of FXN gene to cardiomyocytes is intended to
Slide 9: LX2006 clinical data show sustained or deepening improvements across cardiac measures
LX2006 clinical data show sustained or deepening improvements across cardiac measures of FA; LX2006 generally well tolerated LX2006 generally well tolerated across 17 participants dosed with no Grade 3 treatment-related SAEs to date No clinically significant complement activation Minimal, transient
Slide 10: Cardiac function improvement in individual with later stage cardiomyopathy
Cardiac function improvement observed in individual with later stage cardiomyopathy Effect of LX2006 on Cardiac Function Majority of Participants (16/17) Baseline LVEF: Normal Post therapy: No change One Participant (#13) with later stage cardiomyopathy Baseline LVEF: Low (35%) Post Therapy: Signifi
Slide 11: Change in mFARS: Open Label Cohort vs. UNIFAI Matched Control
Mean Change from Baseline (95% CI) Change in mFARS: Open Label Cohort (n=16) vs. UNIFAI Matched Control (n=45) mFARS validated clinical scale measures FA neurological progression; higher scores represent disease worsening Majority of LX2006-treated participants demonstrate mFARS improvement or stabi
Slide 12: SUNRISE-FA pivotal study design
SUNRISE-FA 2 pivotal study design 1. Eligible participants are those who test negative for neutralizing antibodies to AAVrh10 and meet the LVMI criteria (≥2SD above normal mean). Eligible CLARITY-FA participants or new participants can enroll into the pivotal study1 Stratification to balance baselin
Slide 13: Pivotal study statistical power and key design elements
Mean Reduction in LVMI Phase I/II Mid- and High-Dose Cohorts Phase I/II All Cohorts Pivotal Study Statistical Power Phase I/II data showed clinically meaningful benefit in LVMI improvement >15% SAP powered LVMI effect size Dose 1.2x1012 vg/kg, one-time IV infusion Key Eligibility Criteria Adults (16
Slide 14: Primary endpoint with clinical relevance: LVMI
Primary endpoint with clinical relevance: LVMI Evaluating LVMI at 6 months, SAP powered for 15% or greater reduction Phase I/II data to be submitted for safety and comprehensive BLA review No need for frataxin assay or nonclinical murine bridging study Open label design, with no placebo or sham proc
Slide 15: Strong path forward for LX2006
Strong path forward for LX2006 With Final SUNRISE-FA 2 Protocol, Lexeo Anticipates Potential Topline Data in 2H 2027 and BLA in 1H 2028 SUNRISE-FA 2 to be Initiated in Q2 2026, with First Patient Expected to be Enrolled by End of June Differentiated AAVrh10 Capsid and Commercial-Ready CMC Supply Cha
Slide 16: Thank you
‘therapeutics Thank you